GLP-1 obesity drugs may be best known for their effectiveness and costs, but their influence is now reshaping health care dealmaking. According to Bain & Co.'s Global M&A Report 2026, demand for GLP-1s and next-generation metabolic therapies is helping drive a renewed surge in pharmaceutical mergers and acquisitions.
Strategic pharmaceutical deal value jumped 79% year over year through Nov. 15, 2025, compared with the same period in 2024, as larger average deal sizes signaled a return of confidence in M&A, the report said. While overall health care and life sciences deal counts fell 10% during that period, pharma and biotech accounted for much of the sector's 29% increase in strategic deal value.
At the center of that activity is obesity and metabolic care.
Bain describes a "next-generation obesity treatment gold rush," noting that although GLP-1s and related incretin therapies – medications that mimic gut hormones to help control blood sugar and support weight management – continue to command record deal values, buyer priorities are evolving. Acquirers are no longer focused solely on individual products but are instead pursuing full-platform control, including proprietary delivery technologies, expanded manufacturing capacity and next-generation treatment mechanisms.
"Instead of chasing the molecule, leaders are now aiming to own the platform and the associated profit pool along the value chain," the report noted.
This evolution is also reshaping the structure of deals. Bain said transactions are becoming larger and more technically complex, with many including manufacturing tie-ups designed to ease production bottlenecks. At the same time, companies are broadening their pipelines through investments in oral formulations and dual- and triple-agonist therapies, which target multiple metabolic pathways at once to improve weight loss, blood sugar control and other metabolic outcomes.
Pricing pressure is reinforcing that shift. Medicare's negotiated "maximum fair prices" are set to begin in 2026, and a November 2025 White House agreement to reduce GLP-1 prices while expanding Medicare coverage points to further margin compression. As a result, acquirers are prioritizing scale, efficiency and tighter control over supply chains and commercialization.
Bain also found that among the top 20 pharmaceutical companies, serial acquirers of smaller firms delivered an average total shareholder return of 24% from 2020 to 2025, compared with 6% or less for infrequent and large-scale acquirers. That dynamic is reinforcing a strategy of targeted acquisitions aimed at building capabilities rather than pursuing megadeals.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.